尼麦角林与茴拉西坦治疗脑梗死后轻中度认知功能障碍的临床研究

发布时间：2018-05-28 01:01

本文选题：尼麦角林 + 脑梗死　；参考：《重庆医学》2014年22期

【摘要】：目的观察尼麦角林与茴拉西坦治疗脑梗死后轻中度认知功能障碍的疗效及安全性。方法共入选70例脑梗死后轻中度认知功能障碍的患者,分成尼麦角林治疗组(观察组)和茴拉西坦治疗组(对照组)各35例。治疗12周后,比较两组患者治疗前、后简易精神状态量表(MMSE)、日常生活能力量表(ADL)评分及经颅多普勒(TCD)的改善情况。结果治疗12周后,两组患者MMSE评分较治疗前有明显升高(P0.05),且观察组优于对照组(P0.01);ADL评分较治疗前均有明显下降(P0.05),TCD改善情况观察组优于对照组(P0.01)。结论尼麦角林治疗脑梗死后轻中度认知功能障碍有明显疗效,且优于茴拉西坦,无明显不良反应发生,适合临床广泛应用。
[Abstract]:Objective to observe the efficacy and safety of nicergoline and aniracetam in the treatment of mild and moderate cognitive impairment after cerebral infarction. Methods A total of 70 patients with mild and moderate cognitive impairment after cerebral infarction were divided into two groups: niergoline treatment group (observation group) and aniracetam treatment group (control group). After 12 weeks of treatment, the improvement of MMSE, ADL and TCD were compared between the two groups before and after treatment. Results after 12 weeks of treatment, the MMSE score of the two groups was significantly higher than that of the control group (P 0.05), and that of the observation group was significantly lower than that of the control group (P 0.01), and the improvement of the observation group was better than that of the control group (P 0.01). Conclusion nicergoline has obvious curative effect on mild and moderate cognitive dysfunction after cerebral infarction, and is superior to aniracetam, and has no obvious adverse reaction. It is suitable for clinical wide application.
【作者单位】：重庆市合川区人民医院神经内科;重庆医科大学附属第一医院神经内科;
【分类号】：R749.1;R743.3

【相似文献】